Lisa M Butler1,2, Peter J Meikle3, Lisa G Horvath4,5,6,7,8, Hui-Ming Lin9,10, Kevin Huynh3, Manish Kohli11, Winston Tan12, Arun A Azad13,14,15, Nicole Yeung9, Kate L Mahon9,15,16,17, Blossom Mak9,16,17, Peter D Sutherland18, Andrew Shepherd18,1, Natalie Mellett3, Maria Docanto15, Corey Giles3, Margaret M Centenera1,2. 1. Adelaide Medical School and Freemason's Foundation Centre for Men's Health, University of Adelaide, Adelaide, SA, Australia. 2. South Australian Health and Medical Research Institute, Adelaide, SA, Australia. 3. Baker Heart and Diabetes Institute, Melbourne, VIC, Australia. 4. Garvan Institute of Medical Research, Darlinghurst, Sydney, NSW, Australia. lisa.horvath@lh.org.au. 5. St Vincent's Clinical School, UNSW Sydney, Sydney, NSW, Australia. lisa.horvath@lh.org.au. 6. Chris O' Brien Lifehouse, Camperdown, NSW, Australia. lisa.horvath@lh.org.au. 7. University of Sydney, Sydney, NSW, Australia. lisa.horvath@lh.org.au. 8. Royal Prince Alfred Hospital, Camperdown, NSW, Australia. lisa.horvath@lh.org.au. 9. Garvan Institute of Medical Research, Darlinghurst, Sydney, NSW, Australia. 10. St Vincent's Clinical School, UNSW Sydney, Sydney, NSW, Australia. 11. Division of Oncology, Department of Medicine, Huntsman Cancer Institute, Salt Lake City, UT, USA. 12. Mayo Clinic Florida, Jacksonville, FL, USA. 13. Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. 14. Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia. 15. Monash University, Melbourne, VIC, Australia. 16. Chris O' Brien Lifehouse, Camperdown, NSW, Australia. 17. University of Sydney, Sydney, NSW, Australia. 18. Royal Adelaide Hospital, Adelaide, SA, Australia.
Abstract
BACKGROUND: Dysregulated lipid metabolism is associated with more aggressive pathology and poorer prognosis in prostate cancer (PC). The primary aim of the study is to assess the relationship between the plasma lipidome and clinical outcomes in localised and metastatic PC. The secondary aim is to validate a prognostic circulating 3-lipid signature specific to metastatic castration-resistant PC (mCRPC). PATIENTS AND METHODS: Comprehensive lipidomic analysis was performed on pre-treatment plasma samples from men with localised PC (N = 389), metastatic hormone-sensitive PC (mHSPC)(N = 44), or mCRPC (validation cohort, N = 137). Clinical outcomes from our previously published mCRPC cohort (N = 159) that was used to derive the prognostic circulating 3-lipid signature, were updated. Associations between circulating lipids and clinical outcomes were examined by Cox regression and latent class analysis. RESULTS: Circulating lipid profiles featuring elevated levels of ceramide species were associated with metastatic relapse in localised PC (HR 5.80, 95% CI 3.04-11.1, P = 1 × 10-6), earlier testosterone suppression failure in mHSPC (HR 3.70, 95% CI 1.37-10.0, P = 0.01), and shorter overall survival in mCRPC (HR 2.54, 95% CI 1.73-3.72, P = 1 × 10-6). The prognostic significance of circulating lipid profiles in localised PC was independent of standard clinicopathological and metabolic factors (P < 0.0002). The 3-lipid signature was verified in the mCRPC validation cohort (HR 2.39, 95% CI 1.63-3.51, P = 1 × 10-5). CONCLUSIONS: Elevated circulating ceramide species are associated with poorer clinical outcomes across the natural history of PC. These clinically actionable lipid profiles could be therapeutically targeted in prospective clinical trials to potentially improve PC outcomes.
BACKGROUND: Dysregulated lipid metabolism is associated with more aggressive pathology and poorer prognosis in prostate cancer (PC). The primary aim of the study is to assess the relationship between the plasma lipidome and clinical outcomes in localised and metastatic PC. The secondary aim is to validate a prognostic circulating 3-lipid signature specific to metastatic castration-resistant PC (mCRPC). PATIENTS AND METHODS: Comprehensive lipidomic analysis was performed on pre-treatment plasma samples from men with localised PC (N = 389), metastatic hormone-sensitive PC (mHSPC)(N = 44), or mCRPC (validation cohort, N = 137). Clinical outcomes from our previously published mCRPC cohort (N = 159) that was used to derive the prognostic circulating 3-lipid signature, were updated. Associations between circulating lipids and clinical outcomes were examined by Cox regression and latent class analysis. RESULTS: Circulating lipid profiles featuring elevated levels of ceramide species were associated with metastatic relapse in localised PC (HR 5.80, 95% CI 3.04-11.1, P = 1 × 10-6), earlier testosterone suppression failure in mHSPC (HR 3.70, 95% CI 1.37-10.0, P = 0.01), and shorter overall survival in mCRPC (HR 2.54, 95% CI 1.73-3.72, P = 1 × 10-6). The prognostic significance of circulating lipid profiles in localised PC was independent of standard clinicopathological and metabolic factors (P < 0.0002). The 3-lipid signature was verified in the mCRPC validation cohort (HR 2.39, 95% CI 1.63-3.51, P = 1 × 10-5). CONCLUSIONS: Elevated circulating ceramide species are associated with poorer clinical outcomes across the natural history of PC. These clinically actionable lipid profiles could be therapeutically targeted in prospective clinical trials to potentially improve PC outcomes.
Authors: Maria I Van Rompay; Keith R Solomon; J Curtis Nickel; Gayatri Ranganathan; Philip W Kantoff; John B McKinlay Journal: Eur J Cancer Date: 2019-03-06 Impact factor: 9.162
Authors: Ethan Cerami; Jianjiong Gao; Ugur Dogrusoz; Benjamin E Gross; Selcuk Onur Sumer; Bülent Arman Aksoy; Anders Jacobsen; Caitlin J Byrne; Michael L Heuer; Erik Larsson; Yevgeniy Antipin; Boris Reva; Arthur P Goldberg; Chris Sander; Nikolaus Schultz Journal: Cancer Discov Date: 2012-05 Impact factor: 39.397
Authors: Peter J Meikle; Gerard Wong; Ricardo Tan; Philippe Giral; Paul Robillard; Alexina Orsoni; Neil Hounslow; Dianna J Magliano; Jonathan E Shaw; Joanne E Curran; John Blangero; Bronwyn A Kingwell; M John Chapman Journal: J Lipid Res Date: 2015-10-20 Impact factor: 5.922
Authors: Reijo Laaksonen; Kim Ekroos; Marko Sysi-Aho; Mika Hilvo; Terhi Vihervaara; Dimple Kauhanen; Matti Suoniemi; Reini Hurme; Winfried März; Hubert Scharnagl; Tatjana Stojakovic; Efthymia Vlachopoulou; Marja-Liisa Lokki; Markku S Nieminen; Roland Klingenberg; Christian M Matter; Thorsten Hornemann; Peter Jüni; Nicolas Rodondi; Lorenz Räber; Stephan Windecker; Baris Gencer; Eva Ringdal Pedersen; Grethe S Tell; Ottar Nygård; Francois Mach; Juha Sinisalo; Thomas F Lüscher Journal: Eur Heart J Date: 2016-04-28 Impact factor: 29.983
Authors: Manish Kohli; Winston Tan; Tiantian Zheng; Amy Wang; Carlos Montesinos; Calven Wong; Pan Du; Shidong Jia; Siddhartha Yadav; Lisa G Horvath; Kate L Mahon; Edmond M Kwan; Heidi Fettke; Jianjun Yu; Arun A Azad Journal: EBioMedicine Date: 2020-04 Impact factor: 8.143
Authors: Blossom Mak; Hui-Ming Lin; Thy Duong; Kate L Mahon; Anthony M Joshua; Martin R Stockler; Howard Gurney; Francis Parnis; Alison Zhang; Tahlia Scheinberg; Gary Wittert; Lisa M Butler; David Sullivan; Andrew J Hoy; Peter J Meikle; Lisa G Horvath Journal: Cancers (Basel) Date: 2022-09-30 Impact factor: 6.575
Authors: Blossom Mak; Hui-Ming Lin; Edmond M Kwan; Heidi Fettke; Ben Tran; Ian D Davis; Kate Mahon; Martin R Stockler; Karen Briscoe; Gavin Marx; Alison Zhang; Megan Crumbaker; Winston Tan; Kevin Huynh; Thomas G Meikle; Natalie A Mellett; Andrew J Hoy; Pan Du; Jianjun Yu; Shidong Jia; Anthony M Joshua; David J Waugh; Lisa M Butler; Manish Kohli; Peter J Meikle; Arun A Azad; Lisa G Horvath Journal: BMC Med Date: 2022-03-25 Impact factor: 8.775